fb tracking

Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding insulin icodec

View PDF: Presentation | Summary

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Endocrinologic and Metabolic Drugs Advisory Committee, Public Citizen urged the committee to vote “No” on the question regarding whether Novo Nordisk demonstrated that the benefits of the new once-weekly drug insulin icodec outweigh its risks for improving glycemic control in adults with type 1 diabetes. We discussed how diabetic patients would not be served by premature approval of this inadequately tested new ultra-long-acting insulin.